Failing To Plan Is Planning To Fail: The Case For Early Use Of cGMP Raw Materials

By Beth Kroeger-Fahnestock, Director, New Product Introduction (BioPharma), Avantor, Inc.

Knowing the right time to introduce cGMP raw materials when scaling up mAbs manufacturing avoids production process redevelopment, delays and increased costs, and allows for a seamless transition while maintaining quality and viability.

Learn the key considerations for using high-quality reagents ahead of time. Using cGMP-grade reagents earlier makes for a seamless transition while maintaining quality and viability.